FG Trade/E+ via Getty Images The last time I wrote about AC Immune SA (NASDAQ:ACIU), it was in a Seeking Alpha article entitled “AC Immune: Initial AD Findings Bring About Two Upcoming Catalysts.” In this article, I wrote about the prospects of its anti-Abeta active immunotherapy ACI-24.060 immunotherapy candidate being used to treat patients with Alzheimer's Disease [AD]. The use of this vaccine immunotherapy is currently being explored in the ongoing phase 2 ABATE trial. This trial is split up into ta ...